Stocktwits on MSN
Biohaven’s phase II depression trial falls short, but analysts downplay impact – Wall Street looks ahead to epilepsy data
Analyst Myles Minter noted that the company’s pivotal Phase III study of BHV-7000 in focal-onset epilepsy in the first half ...
Navacaprant did not statistically significantly improve MADRS total score or SHAPS total score compared with placebo. Topline data were announced from a phase 3 trial evaluating navacaprant for the ...
Major depressive disorder (MDD) is a debilitating psychiatric condition characterized by a persistently low mood, a lack of ...
Explore therapeutic choices for patients with treatment-resistant depression, including ketamine, psilocybin, and various ...
Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit from short-term nitrous oxide treatment, a major meta-analysis led by the ...
Major depressive disorder (MDD) is a leading cause of disability in millions of people worldwide. Importantly, the gut microbiome can contribute to stress-related responses in patients experiencing ...
A large England study found fewer NHS visits for sleep, heart, and mental health issues after clocks moved back in autumn.
Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not gotten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback